Servier’s Acquisition of an Agios Pharmaceuticals Business

Servier's Acquisition of an Agios Pharmaceuticals Business

Baker McKenzie advised Servier on the deal.

Servier completed the acquisition of Agios  Pharmaceuticals’s oncology business. The transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties.

Agios Pharmaceuticals specializes in research and development of drugs for the treatment of hematologic malignancies.

Baker McKenzie team was led by partner Stéphane Davin (Picture), and associate Elsa Lesclide, partner Léna Sersiron and Michael DeFranco.

Laboratoires Servier’s internal team was made up of Benoit Chéron, Corporate Law Director, Matthieu Guerineau, Director of the Contracts department, Jawad Fassi-Fehri, Senior Corporate Law Legal Adviser, Mayalen Lacabarats, Head of the Contratcs department division. 

Involved fees earner: Stéphane Davin – Baker McKenzie; Michael DeFranco – Baker McKenzie; Elsa Lesclide – Baker McKenzie; Léna Sersiron – Baker McKenzie;

Law Firms: Baker McKenzie;

Clients: Servier;